Combined therapy against tumors comprising substituted...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/70 (2006.01) A61K 31/335 (2006.01) A61K 31/40 (2006.01) A61K 31/475 (2006.01) A61K 31/505 (2006.01) A61K 31/565 (2006.01) A61K 31/7064 (2006.01) A61K 45/06 (2006.01)

Patent

CA 2412054

The present invention provides the combined use of acryloyl distamycin derivatives, in particular .alpha.-bromo- and -.alpha.-chloro-acryloyl distamycin derivatives of formula (I), as set forth in the specification, antimicrotubule agents and/or an antimetabolites. Also provided is the use of the said combination in the treatment or prevention of metastasis or in the treatment of tumors by inhibition of angiogenesis.

La présente invention concerne l'utilisation combinée de dérivés acryloyl-distamycine substitués, et en particulier de .alpha.-bromo- et -.alpha.-chloro-acryloyl-distamycine représentés par la formule (I), tels qu'ils sont décrits dans la spécification, d'anti-microtubules, et/ou d'antimétabolites. L'invention concerne également l'utilisation de cette combinaison pour le traitement et/ou la prévention de la métastase, ou pour le traitement de tumeurs par inhibition de l'angiogenèse.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Combined therapy against tumors comprising substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combined therapy against tumors comprising substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined therapy against tumors comprising substituted... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1474767

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.